Tatva Chintan Pharma Chem Limited (TATVA) fundamentals
Tatva Chintan Pharma Chem Limited is a listed company in Chemicals & Petrochemicals, part of the Chemicals sector, listed on the NSE as TATVA (ISIN INE0GK401011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Tatva Chintan Pharma Chem Limited does
Tatva Chintan Pharma Chem Limited is an India-based specialty chemical manufacturing company. The Company is engaged in the manufacturing of a variety of chemicals, including structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts and solutions (ESS) for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are used for forming channels in zeolites. Its PTCs are used in heterogeneous multiphase systems, facilitating reactant migration. It operates through the Specialty chemical segment. The Company operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. It caters to various customers across various industries, including the automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances industries. The Company’s subsidiaries are Tatva Chintan Europe B.V. and Tatva Chintan USA Inc.
Valuation and market data
| Last close | ₹1608.70 |
|---|---|
| Market capitalisation | ₹3,762 crore |
| Enterprise value | ₹3,765 crore |
| P/E (TTM) | 89.47 |
| Price to book | 4.81 |
| Price to sales (TTM) | 4.03 |
| Book value per share | ₹334.27 |
| Dividend yield | 6.22% |
| Sector | Chemicals |
| Industry | Chemicals & Petrochemicals |
| Listed since | Thu Jul 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹500 crore | ₹53 crore | ₹39 crore | 16.71 |
| Mar 2025 | ₹370 crore | ₹0 crore | ₹0 crore | 0.14 |
| Mar 2024 | ₹386 crore | ₹42 crore | ₹29 crore | 12.82 |
| Mar 2023 | ₹409 crore | ₹39 crore | ₹40 crore | 18.26 |
| Mar 2022 | ₹438 crore | ₹103 crore | ₹96 crore | 44.65 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.0% |
|---|---|
| Foreign institutions (FII) | 3.9% |
| Mutual funds | 2.8% |
| Other domestic institutions | 0.3% |
| Retail and others | 20.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.